Article
GT Vector Manufacturing Process — The CMC Foundation CBER Reviewers Evaluate First
CBER Office of Therapeutic Products (OTP) reviewers have seen thousands of gene therapy INDs. The ones that stall are not missing data — they are missing process understanding.
XGene Articles & Analysis
Evidence-led analysis for decisions that matter.
Senior-authored regulatory, CMC, GMP, quality, and inspection analysis designed for practical use—not passive reading.
01SignalSource evidence
02InterpretTechnical judgment
03ApplyDecision pathway
Publication library
Keep moving from evidence to decision.
Article
GT Vector Manufacturing Process — The CMC Foundation CBER Reviewers Evaluate First
CBER Office of Therapeutic Products (OTP) reviewers have seen thousands of gene therapy INDs. The ones that stall are not missing data — they are missing process understanding.
Article
CMC Technology Landscape — Vendor Survey and Selection Framework
Pharmaceutical companies are spending millions of dollars on CMC technology platforms — LIMS, ELN, stability software, document management, regulatory information management — without a selection framework that accounts…
Article
Emerging Biologic Modalities — VHH Nanobodies, DARPins, and Non-IgG Biologic CMC Frameworks
The mAb CMC team that transitions to a VHH nanobody program brings CHO cell culture expertise, ICH Q6B characterization protocols, Protein A purification experience, and Fc-effector-function potency assay…
Article
CMC Single Source of Truth — Architecture for the Integrated Data System
The most expensive compliance problem in pharmaceutical CMC is not having wrong data — it is having the right data in four different places, in four different formats,…
Article
Platform Process for mAbs — The Regulatory Case for Platform Approaches and CMC Development Efficiency
The platform process argument is made in the boardroom to justify R&D cost efficiency and in the CMC strategy meeting to justify reduced analytical burden. The problem is…
Article
NLP for Regulatory Affairs — CMC Intelligence Extraction Capabilities
Natural Language Processing is already being used in pharmaceutical regulatory affairs to extract intelligence from FDA guidance documents, Warning Letters, and competitor submissions — and the CMC teams…
Article
Fc Engineering and Glycoengineering — CMC Implications for Engineered mAb Drug Substances
An engineered Fc domain — LALA-silenced, YTE half-life-extended, or GASDALIE-enhanced — is not a standard IgG Fc with a mutation footnote in the sequence listing. Each engineering strategy…
Article
Regulatory Submission APIs and Workflows — Automating the CMC Pipeline
The manual, document-centric process of assembling a CMC regulatory submission — exporting data from LIMS, pasting it into Word tables, formatting it for eCTD, and cross-referencing it across…
Article
High-Concentration Antibody Formulations — CMC Challenges for Subcutaneous Delivery Programs
A high-concentration antibody formulation isn't a standard mAb formulation scaled up in concentration — above roughly 100 mg/mL, viscosity becomes a manufacturability and deliverability constraint in its own…
Article
FAIR Data Applied to Pharmaceutical CMC — The Practical Implementation
Every pharmaceutical company that has committed to FAIR data principles has a beautiful diagram showing how their CMC data will be Findable, Accessible, Interoperable, and Reusable — and…
Article
Protein Drug Formulation Stability — Aggregation, Deamidation, and the Formulation Development Package
A protein drug formulation development package that runs one pH condition, one temperature, and calls the stability program complete is not a formulation development package — it is…
Article
CDISC Standards in CMC — Where the Intersection with Regulatory Science Sits
CDISC standards — the Clinical Data Interchange Standards Consortium — are well established in clinical trial data management, but their intersection with pharmaceutical CMC is less understood and…
Read with purpose
Every analysis should make the next move clearer.
- 01ReadUnderstand the technical argument.
- 02TraceFollow evidence and regulatory context.
- 03CompareExplore related XGene intelligence.
- 04ActConnect the issue to a practical pathway.